Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Paul M BarrAlessandra TedeschiWilliam G WierdaJohn N AllanPaolo GhiaDaniele VallisaRyan JacobsSusan M O'BrienAndrew P GriggPatricia WalkerCathy ZhouJoi NinomotoGabriel KrigsfeldConstantine S TamPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Three cycles of ibrutinib lead-in before venetoclax initiation provides effective tumor debulking, decreases the TLS risk category and reduces the need for hospitalization for intensive monitoring for TLS.